Literature DB >> 11678618

Management of chronic hepatitis B infection: an update.

T N Mazumdar1.   

Abstract

Almost 43 million people in India are harbouring hepatitis B virus (HBV) in their blood. Chronic HBV infection may be with or without sign/symptom of liver disease. Children are more prone to suffer from chronic HBV infection compared to adults and adolescents. Treatment aims at prevention of its sequelae namely cirrhosis and subsequent hepatocellular carcinoma. At the moment two major groups of agents are available for treatment. These are (a) immunomodulators and (b) antivirals. Present research aims at identification of a suitable agent to act on HBV covalently closed circular DNA persisting in hepatic cells for complete eradication of HBV.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11678618

Source DB:  PubMed          Journal:  J Indian Med Assoc        ISSN: 0019-5847


  5 in total

1.  Effects of autoantibodies against beta(1)-adrenoceptor in hepatitis virus myocarditis on action potential and L-type Ca(2+) currents.

Authors:  Kun Liu; Yu-Hua Liao; Zhao-Hui Wang; Shu-Li Li; Ming Wang; Ling-Lan Zeng; Ming Tang
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

2.  VP22 fusion protein-based dominant negative mutant can inhibit hepatitis B virus replication.

Authors:  Jun Yi; Wei-Dong Gong; Ling Wang; Rui Ling; Jiang-Hao Chen; Jun Yun
Journal:  World J Gastroenterol       Date:  2005-11-07       Impact factor: 5.742

3.  Inhibition on Hepatitis B virus in vitro of recombinant MAP30 from bitter melon.

Authors:  Jian Ming Fan; Qiao Zhang; Jun Xu; Sha Zhu; Tao Ke; De Fu Gao; Yu Bao Xu
Journal:  Mol Biol Rep       Date:  2007-12-05       Impact factor: 2.316

4.  Anti-HBV activity of TRL mediated by recombinant adenovirus.

Authors:  Wei-Dong Gong; Ya Zhao; Jun Yi; Jin Ding; Jun Liu; Cai-Fang Xue
Journal:  World J Gastroenterol       Date:  2005-05-07       Impact factor: 5.742

5.  Inhibition of HBV targeted ribonuclease enhanced by introduction of linker.

Authors:  Wei-Dong Gong; Jun Liu; Jin Ding; Ya Zhao; Ying-Hui Li; Cai-Fang Xue
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.